Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Status:
Completed
Trial end date:
2006-08-15
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an
effective treatment for recurrent glioma and meningioma.
PURPOSE: Phase I/II trial to study the effectiveness of imatinib mesylate in treating
patients who have progressive, recurrent, or unresectable malignant glioma or meningioma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
North American Brain Tumor Consortium Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins